Results 41 to 50 of about 2,882,240 (203)

Canary in the Coal Mine? Transmitted Mutations Conferring Resistance to All Integrase Strand Transfer Inhibitors in a Treatment-Naive Patient.

, 2020
Transmitted drug resistance to the integrase strand transfer inhibitor (INSTI) class of antiretrovirals is very rare. We present a case of a treatment-naive female patient with human immunodeficiency virus harboring resistance to all INSTIs, including ...
Okeke, Nwora Lance, Hurt, Christopher B, McGee, Kara S, McKellar, Mehri S   +3 more
core   +1 more source

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

Southern African Journal of HIV Medicine, 2020
Introduction: The integrase strand transfer inhibitor dolutegravir (DTG) has a high genetic barrier to resistance. Only rare cases of resistance to DTG have been reported when it is used as a component of antiretroviral therapy regimens in treatment ...
Kairoonisha Mahomed, Carole L. Wallis, Liezl Dunn, Shavani Maharaj, Gary Maartens, Graeme Meintjes   +5 more
doaj   +1 more source

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia

Viruses, 2022
Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing countries, including Ethiopia. However, subtype-dependent polymorphic differences might influence the occurrence of HIV-drug-resistance mutations (HIVDRMs). We analyzed
Dawit Assefa Arimide, Zsófia Ilona Szojka, Kidist Zealiyas, Atsbeha Gebreegziabxier, Fekadu Adugna, Sviataslau Sasinovich, Per Björkman, Patrik Medstrand   +7 more
doaj   +1 more source

Integrase strand transfer inhibitors in the management of HIV-positive individuals

Annals of Medicine, 2014
The use of highly active antiretroviral therapy against human immunodeficiency virus (HIV) can lead to rare instances of treatment failure and the emergence of drug resistance. HIV drug-resistant strains are archived in cellular reservoirs, and this can exclude the future efficacy of drugs or drug classes against which resistance has emerged.
Thibault, Mesplède, Peter K, Quashie, Veronica, Zanichelli, Mark A, Wainberg   +3 more
openaire   +2 more sources

Dolutegravir-Associated Hyperglycemia in a Patient on Highly Active Antiretroviral Therapies

Nigerian Journal of Medicine
Highly active antiretroviral medications have been reported to cause hyperglycaemia in the literature especially the protease inhibitor. We however report a case of dolutegravir-associated hyperglycaemia which is an integrase strand transfer inhibitor.
Abosede Grace Adeyeye, Victor Oladeji Adeyeye   +1 more
doaj   +1 more source

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Journal of the International Association of Providers of AIDS Care, 2019
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus ...
Niccolò Riccardi MD, Filippo Del Puente MD, Lucia Taramasso MD, Antonio Di Biagio MD   +3 more
doaj   +1 more source

Design, synthesis, molecular dynamics studies and biological evaluations of 4-hydroxy-5-pyrrolinone-3-carbohydrazides as HIV-1 integrase inhibitors

European Journal of Medicinal Chemistry Reports
Acquired immune deficiency syndrome (AIDS) diseases despite the efficacy of anti-HIV therapy, remain one of the human's most serious problems. Hence, the introduction of novel anti-HIV agents as first-line therapy is still required. HIV integrase lacking
Nafiseh Karimi, Amirreza Dowlati Beirami, Rouhollah Vahabpour Roudsari, Zahra Hajimahdi, Afshin Zarghi   +4 more
doaj   +1 more source

HIV drug resistance against strand transfer integrase inhibitors

Retrovirology, 2017
Integrase strand transfer inhibitors (INSTIs) are the newest class of antiretroviral drugs to be approved for treatment and act by inhibiting the essential HIV protein integrase from inserting the viral DNA genome into the host cell's chromatin. Three drugs of this class are currently approved for use in HIV-positive individuals: raltegravir (RAL ...
Kaitlin Anstett, Bluma Brenner, Thibault Mesplede, Mark A. Wainberg   +3 more
openaire   +3 more sources

Table_1_Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro.DOCX

, 2022
Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus most prevalent in southwestern Japan, sub-Saharan Africa, Australia, South America, and the Caribbean. Latest figures approximate 10 million people worldwide to be infected with HTLV-1.
Bethany S. Schneiderman (12452517), Michal S. Barski (12452520), Goedele N. Maertens (7213850)   +2 more
core   +1 more source

HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe. [PDF]

, 2021
Previously used as part of salvage therapy, integrase strand transfer inhibitors (INSTIs) have become part of the preferred antiretroviral therapy (ART) first-line regimen in most low- to middle-income countries. With the extensive use of dolutegravir in
Manasa, Justen, Shamu, Tinei, Kouamou, Vinie, Katzenstein, David, Dhoro, Milcah, Madyadi, Amanda, Washaya, Tendai, Chimukangara, Benjamin   +7 more
core   +1 more source